Loading stock data…
Rocket Pharmaceuticals (RCKT)
$3.37+0.12 (+3.69%)
After Hours$3.35-0.02 (-0.59%)· Last close Jun 29
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Rocket Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.37 with a market capitalization of $308M. Wall Street consensus targets $9.39 (11 analysts), implying a +178.5% move over the next 12 months. The stock is currently 38% below its 52-week high of $5.45, remaining 5.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 73 is overbought against a weak tape. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +178.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 73 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.51M↓ | -$44.03M↑ | -$52.42M↑ | -$67.68M↓ | -$64.39M |
| Net Income | -$47.59M↓ | -$42.54M↑ | -$50.33M↑ | -$68.92M↓ | -$61.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$307.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-87.96%
Volume
Today's trading volume
1.62M
Recent News
Is Rocket Pharmaceuticals, Inc. (RCKT) Poised for Recovery After Key Gene Therapy Program Milestone?
We recently compiled a list of the 10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds. Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is one of the most promising stocks on our list. TheFly reported on June 3 that BofA Securities analyst Jason Zemansky increased the price target on RCKT to $10 from $9 while maintaining a Buy […]
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Where’s the Stock Going?
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is one of the best gene therapy stocks to buy in 2026. The Street expects Rocket Pharmaceuticals’ stock to explode 180% over the next 12 months. On April 28, Leerink Partners boosted its price target on Rocket Pharmaceuticals shares to $12 from $11 while keeping a Market Perform rating on the […]
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M
Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best NASDAQ stocks under $5 to buy right now. On May 7, Rocket Pharmaceuticals reported a Q1 2026 net loss of $47.6 million ($0.42 per share). Driven by a recent realignment and lower headcount, R&D expenses fell to $31.5 million, and G&A expenses dropped to $17.1 million. […]
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
Rocket Pharmaceuticals' (RCKT) clinical and regulatory updates on its three cardiac gene therapy pro